Cargando…

COVID-19 convalescent plasma transfusion

Detalles Bibliográficos
Autores principales:	Langhi, Dante Mário, Santis, Gil Cunha De, Bordin, José Orlando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2020
Materias:	Special Scientific Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164882/ https://www.ncbi.nlm.nih.gov/pubmed/32313872 http://dx.doi.org/10.1016/j.htct.2020.04.003

Ejemplares similares

Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19
por: De Santis, Gil Cunha, et al.
Publicado: (2021)

SARS-COV-2: is it a risk for blood transfusion?
por: Langhi, Dante Mário, et al.
Publicado: (2022)

Blood donation, blood supply, iron deficiency and anemia - it is time to shift attention back to donor health
por: Cançado, Rodolfo Delfini, et al.
Publicado: (2012)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma in patients hospitalised with COVID-19
por: Liu, Sean T H, et al.
Publicado: (2021)

Convalescent plasma as a potential therapy for COVID-19
por: Chen, Long, et al.
Publicado: (2020)

Convalescent plasma from people vaccinated after COVID-19 infection
por: Jabal, Kamal Abu, et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: De Santis, Gil C., et al.
Publicado: (2022)

Guidelines on transfusion of red blood cells: Prognosis of patients who decline blood transfusions
por: Langhi, Dante Mário, et al.
Publicado: (2018)

Hemovigilance: a system to improve the whole transfusion chain
por: Carneiro-Proietti, Anna Barbara de Freitas
Publicado: (2013)

Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion
por: Farhat, Ryan M., et al.
Publicado: (2020)

Convalescent plasma transfusion for pregnant patients with COVID-19
por: Mastroianni, Antonio, et al.
Publicado: (2021)

Applying molecular immunohematology discoveries to daily transfusion practice
por: Castilho, Lilian
Publicado: (2012)

The role of hemovigilance as a mechanism to increase transfusion safety
por: Moraes-Souza, Hélio
Publicado: (2011)

Comments on: Alloimmunization screening after transfusion of red blood cells in a prospective study
por: de Melo, Laércio
Publicado: (2012)

Comments on: Frequency of human platelet antigens in oncohematological patients with thrombocytopenia and the probability of incompatibility to platelet transfusions
por: de Paula, Erich Vinicius
Publicado: (2012)

Plasma exchange followed by convalescent plasma transfusion in COVID-19 patients
por: Roshandel, Elham, et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response)
por: De Santis, Gil C., et al.
Publicado: (2022)

Comments on the participation in proficiency programs and promotion of quality in transfusion services of Minas Gerais
por: Bianco, Celso
Publicado: (2012)

Development and implementation of a COVID-19 convalescent plasma program in a middle-income economy
por: Duarte, Gustavo de Carvalho, et al.
Publicado: (2022)

Comment on: Transfusion practices in a neonatal intensive care unit in a Brazilian town()
por: dos Santos, Amelia Miyashiro Nunes
Publicado: (2014)

Comments on the clinical and laboratory characteristics of patients with dengue hemorrhagic fever manifestations and their transfusion profile
por: Lemes, Romélia Pinheiro Gonçalves
Publicado: (2014)

Molecular assays as tools to facilitate new discoveries and to enhance immunohematology in daily transfusion practice
por: Rios, Maria
Publicado: (2013)

Clinical outcomes of using plasma in COVID-19 convalescent critically ill patients
por: Astola Hidalgo, I., et al.
Publicado: (2023)

Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections
por: Epstein, Jay, et al.
Publicado: (2020)

We need to talk more about transfusion-transmitted malaria in Plasmodium vivax endemic areas()
por: Lacerda, Marcus Vinícius Guimarães, et al.
Publicado: (2014)

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19
por: So-Osman, Cynthia, et al.
Publicado: (2022)

Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Farag, Youssef M.K.
Publicado: (2020)

Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19
por: Rodionov, Roman N, et al.
Publicado: (2021)

Clinical nursing care protocol for convalescent plasma transfusion in patients with COVID-19
por: Maiara Ferreira Barreto Pires, Bruna, et al.
Publicado: (2023)

In Reply — Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Joyner, Michael. J., et al.
Publicado: (2020)

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. V: Manufacture and quality control
por: De Santis, Gil Cunha, et al.
Publicado: (2021)

Characterization of pathogen‐inactivated COVID‐19 convalescent plasma and responses in transfused patients
por: Weisser, Maja, et al.
Publicado: (2022)

Convalescent Plasma Transfusion for the Treatment of COVID-19 in Adults: A Global Perspective
por: Kanj, Saly, et al.
Publicado: (2021)

Guidelines on Beta-thalassemia major – regular blood transfusion therapy: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: project guidelines: Associação Médica Brasileira – 2016
por: Langhi, Dante, et al.
Publicado: (2016)

Therapeutic plasma exchange followed by convalescent plasma transfusion in critical COVID-19—An exploratory study
por: Jaiswal, Vinod, et al.
Publicado: (2021)

COVID and hematology: special considerations regarding patient safety, gold standard therapies and safety for health care professionals()
por: Garnica, Marcia, et al.
Publicado: (2020)

Plasminogen and fibrinogen plasma levels in coronary artery disease
por: Kazmi, Rashid S., et al.
Publicado: (2012)

Blood and Plasma Transfusion
por: Napier, L. Everard
Publicado: (1942)

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VI: Accreditation process
por: De Santis, Gil Cunha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3p67v97vtvnd1e7196k2sg2d2c